Patents by Inventor Manfred Rieger
Manfred Rieger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150023978Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: ApplicationFiled: January 17, 2014Publication date: January 22, 2015Applicants: Baxter International Inc., Dyax Corp., Baxter Healthcare SAInventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Patent number: 8668909Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: GrantFiled: April 26, 2010Date of Patent: March 11, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A., Dyax Corp.Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Patent number: 8586538Abstract: The present invention concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or prolong Factor VIII half-life in a biological fluid and/or a method to treat patients suffering from a blood coagulation disorder, especially Haemophilia A. The present invention also concerns a pharmaceutical composition useful for the decrease of Factor VIII degradation in a biological fluid, the inhibition of Factor VIII interaction with LRP, and/or the prolongation of Factor VIII half-life in a biological fluid for treatment of a blood coagulation disorder, especially Haemophilia A.Type: GrantFiled: April 28, 2003Date of Patent: November 19, 2013Assignee: Stichting Sanquin BloedvoorzieningInventors: Koenraad Mertens, Arend N. Bovenschen, Jan Voorberg, Manfred Rieger, Friedrich Scheiflinger
-
Patent number: 7943326Abstract: This invention relates to a kit to be used in an assay system for determination of an anti-von Willebrand Factor-cleaving protease (“anti-vWF-cp”) antibody in a sample. The kit comprises vWF-cp and/or vWF-fragment(s) immobilized on a solid phase. The kit can be used in a method for determination of anti-vWF-cp antibodies from a patient, for the diagnosis of disorders associated with the occurrence of anti-vWF-cp-antibodies, and the differentiation of various forms of thrombotic microangiopathy.Type: GrantFiled: July 2, 2010Date of Patent: May 17, 2011Assignees: Baxter Health S.A., Baxter International, Inc.Inventors: Friedrich Scheiflinger, Manfred Rieger, Barbara Plaimauer
-
Publication number: 20100273183Abstract: This invention relates to a kit to be used in an assay system for determination of an anti-von Willebrand Factor-cleaving protease (“anti-vWF-cp”) antibody in a sample. The kit comprises vWF-cp and/or vWF-fragment(s) immobilized on a solid phase. The kit can be used in a method for determination of anti-vWF-cp antibodies from a patient, for the diagnosis of disorders associated with the occurrence of anti-vWF-cp-antibodies, and the differentiation of various forms of thrombotic microangiopathy.Type: ApplicationFiled: July 2, 2010Publication date: October 28, 2010Applicants: Baxter Healthcare S.A., Baxter International, Inc.Inventors: Friedrich Scheiflinger, Manfred Rieger, Barbara Plaimauer
-
Publication number: 20100260768Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: ApplicationFiled: April 26, 2010Publication date: October 14, 2010Applicants: Baxter International Inc., Baxter Healthcare S.A., Dyax Corp.Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Patent number: 7763430Abstract: This invention relates to a kit to be used in an assay system for determination of an anti-von Willebrand Factor-cleaving protease (“anti-vWF-cp”) antibody in a sample. The kit comprises vWF-cp and/or vWF-fragment(s) immobilized on a solid phase. The kit can be used in a method for determination of anti-vWF-cp antibodies from a patient, for the diagnosis of disorders associated with the occurrence of anti-vWF-cp-antibodies, and the differentiation of various forms of thrombotic microangiopathy.Type: GrantFiled: April 22, 2003Date of Patent: July 27, 2010Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Friedrich Scheiflinger, Manfred Rieger, Barbara Plaimauer
-
Publication number: 20090220521Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.Type: ApplicationFiled: December 30, 2008Publication date: September 3, 2009Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
-
Publication number: 20080219983Abstract: The present invention concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or prolong Factor VIII half-life in a biological fluid and/or a method to treat patients suffering from a blood coagulation disorder, especially Haemophilia A. The present invention also concerns a pharmaceutical composition useful for the decrease of Factor VIII degradation in a biological fluid, the inhibition of Factor VIII interaction with LRP, and/or the prolongation of Factor VIII half-life in a biological fluid for treatment of a blood coagulation disorder, especially Haemophilia A.Type: ApplicationFiled: April 28, 2003Publication date: September 11, 2008Applicant: TRIMESTER CUSHION COMPANYInventors: Koenraad Mertens, Arend Bovenschen, Johannes Jacobus Voorberg, Manfred Rieger, Friedrich Scheiflinger
-
Publication number: 20040214346Abstract: This invention relates to a kit to be used in an assay system for determination of an anti-von Willebrand Factor-cleaving protease (“anti-vWF-cp”) antibody in a sample. The kit comprises vWF-cp and/or vWF-fragment(s) immobilized on a solid phase. The kit can be used in a method for determination of anti-vWF-cp antibodies from a patient, for the diagnosis of disorders associated with the occurrence of anti-vWF-cp-antibodies, and the differentiation of various forms of thrombotic microangiopathy.Type: ApplicationFiled: April 22, 2003Publication date: October 28, 2004Inventors: Friedrich Scheiflinger, Manfred Rieger, Barbara Plaimauer
-
Patent number: 6670116Abstract: Methods are disclosed that permit pathogenic agent detection and differentiation between infectious and non-infectious forms. Specifically, the present invention provides for pathogenic agent detection using nucleic acid amplification and detection techniques. Moreover, these nucleic acid amplification and detection techniques permit infectious pathogens to be distinguished from non-infectious forms. Also disclosed is a method used to detect and distinguishes between infectious and non-infectious pathogens in biological products and pharmaceutical preparations.Type: GrantFiled: December 20, 2000Date of Patent: December 30, 2003Assignee: Baxter AktiengesellschaftInventors: Klaus Zimmermann, Dirk Völkel, Peter Turecek, Hans-Peter Schwarz, Manfred Rieger
-
Publication number: 20020102548Abstract: Internal nucleic acid standards for nucleic acid amplification assays are provided. Specifically, internal nucleic acid standards are provided that are prepared using non-recombinant DNA technology. These internal nucleic acid standards are generally chemically synthesized and have a minimum size of approximately 90 nucleic acid bases. Also provided are internal nucleic acid standards prepared using non-recombinant DNA techniques that are single stranded nucleic acids.Type: ApplicationFiled: December 20, 2000Publication date: August 1, 2002Applicant: Baxter AktiengesellschaftInventors: Klaus Zimmermann, Peter Turecek, Hans-Peter Schwarz, Manfred Rieger
-
Publication number: 20010034020Abstract: Methods are disclosed that permit pathogenic agent detection and differentiation between infectious and non-infectious forms. Specifically, the present invention provides for pathogenic agent detection using nucleic acid amplification and detection techniques. Moreover, these nucleic acid amplification and detection techniques permit infectious pathogens to be distinguished from non-infectious forms. Also disclosed is a method used to detect and distinguishes between infectious and non-infectious pathogens in biological products and pharmaceutical preparations.Type: ApplicationFiled: December 20, 2000Publication date: October 25, 2001Applicant: Baxter AktiengesellschaftInventors: Klaus Zimmermann, Dirk Volkel, Peter Turecek, Hans-Peter Schwarz, Manfred Rieger
-
Patent number: 4563574Abstract: A hub odometer having a protective case adapted to be mounted axially on an axle cap of a vehicle with a substantially cylindrical carrier plate rotatably mounted in the case for supporting a counting mechanism having figure wheels. The shaft of the figure wheels is mounted transversely of the axis of rotation of the case within the carrier plate, and a reduction gearing transfers the relative rotation of case and carrier plate to the figure wheels. At least one ball of heavy metal is provided, the ball being movably positioned in substantially diametrical opposition with respect to the case axis to the figure wheels, the ball being heavier than the counting mechanism.Type: GrantFiled: September 28, 1984Date of Patent: January 7, 1986Assignee: Jost-Werke GmbHInventors: Hans Dreyer, Manfred Rieger
-
Patent number: 3944606Abstract: Alkali metal or ammonium citrates are produced from solutions of citric acid obtained by chemical reaction or by fermentation by extraction by means of a specific water-immiscible mixture of aliphatic amines and organic solvents and re-extracting the resulting organic solvent mixture with an aqueous solution of an alkali metal hydroxide, carbonate or bicarbonate, ammonia, or their salts.Type: GrantFiled: October 29, 1974Date of Patent: March 16, 1976Assignee: Joh. A. Benckiser GmbHInventors: Manfred Rieger, Johannes Kioustelidis